| |
| |
| Exchange: |
N/A |
| Security
Type: |
Common |
| Shares
Out: |
65,540,000 |
| Market
Cap: |
4.26(B) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$8.54 - $64.97 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Alpine Immune Sciences is a clinical-stage biopharmaceutical company focused on discovering and developing protein-based immunotherapies to treat cancer and autoimmune and inflammatory diseases. Co.'s ALPN-101 (acazicolcept) is a dual Inducible T cell Costimulator and cluster of differentiation 28 (CD28) antagonist intended for the treatment of autoimmune and inflammatory diseases. Co.'s ALPN-303 is a dual B cell cytokine antagonist, being developed for the treatment of B cell mediated inflammatory and autoimmune diseases. Co.'s primary oncology program is ALPN-202 (davoceticept) is a conditional CD28 costimulator and dual checkpoint inhibitor intended for the treatment of cancer.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
750,000 |
750,000 |
| Total Buy Value |
$0 |
$0 |
$9,375,000 |
$9,375,000 |
| Total People Bought |
0 |
0 |
2 |
2 |
| Total Buy Transactions |
0 |
0 |
2 |
2 |
| Total Shares Sold |
19 |
3,303,613 |
3,587,529 |
3,587,529 |
| Total Sell Value |
$1,227 |
$61,976,608 |
$66,912,708 |
$66,912,708 |
| Total People Sold |
1 |
5 |
5 |
5 |
| Total Sell Transactions |
1 |
11 |
24 |
24 |
| End Date |
2024-03-21 |
2023-12-19 |
2023-06-20 |
2022-06-20 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Decheng Capital Management Iii (cayman), Llc |
10% Owner |
– – • |
2022-09-23 |
4 |
A |
$7.35 |
$9,999,998 |
I/I |
1,360,544 |
1,360,544 |
|
- |
|
| Decheng Capital Management Iii (cayman), Llc |
10% Owner |
– – • |
2022-09-23 |
4 |
A |
$7.35 |
$4,700,002 |
D/D |
639,456 |
5,347,744 |
|
- |
|
| Venkatesan Jay |
Director |
– • • |
2022-07-15 |
4 |
OE |
$0.45 |
$9,028 |
D/D |
20,063 |
238,126 |
|
- |
|
| Topper James N |
Director |
– • • |
2022-02-11 |
4 |
B |
$7.10 |
$799,989 |
D/D |
112,665 |
1,484,115 |
3.92 |
24% |
|
| Rickey James Paul |
Senior VP and CFO |
• – – |
2021-12-31 |
4 |
S |
$13.92 |
$236,756 |
D/D |
(17,013) |
7,014 |
|
49% |
|
| Peetz Christopher |
Director |
– • – |
2021-09-23 |
4/A |
B |
$10.17 |
$19,323 |
I/I |
1,900 |
1,900 |
2.1 |
- |
|
| Conway Robert |
Director |
– • – |
2021-09-23 |
4/A |
B |
$10.08 |
$151,154 |
I/I |
15,000 |
50,000 |
2.1 |
- |
|
| Peetz Christopher |
Director |
– • – |
2021-09-23 |
4 |
S |
$10.17 |
$19,323 |
I/I |
(1,900) |
1,900 |
|
32% |
|
| Conway Robert |
Director |
– • – |
2021-09-23 |
4 |
S |
$10.08 |
$151,154 |
I/I |
(15,000) |
50,000 |
|
32% |
|
| Conway Robert |
Director |
– • – |
2021-09-21 |
4 |
B |
$9.80 |
$97,966 |
I/I |
10,000 |
35,000 |
2.1 |
-17% |
|
| Thompson Peter A |
Director |
– • • |
2021-09-17 |
4 |
B |
$9.40 |
$9,499,988 |
I/I |
1,010,637 |
425,531 |
2.25 |
-19% |
|
| Alpine Bioventures Gp, Llc |
10% Owner |
– – • |
2021-09-17 |
4 |
S |
$9.40 |
$3,760,000 |
D/D |
(400,000) |
2,600,980 |
|
19% |
|
| Orbimed Genesis Gp Llc |
Director |
– • • |
2021-09-17 |
4 |
B |
$9.40 |
$9,499,988 |
I/I |
1,010,637 |
425,531 |
2.25 |
-19% |
|
| Decheng Capital Management Iii (cayman), Llc |
10% Owner |
– – • |
2021-09-17 |
4 |
B |
$9.40 |
$14,499,998 |
D/D |
1,542,553 |
4,708,288 |
2.45 |
-19% |
|
| Cui Xiangmin |
Director |
– • • |
2021-09-17 |
4 |
B |
$9.40 |
$14,499,998 |
I/I |
1,542,553 |
4,708,288 |
2.25 |
-19% |
|
| Venkatesan Jay |
Director |
– • • |
2021-09-17 |
4 |
S |
$9.40 |
$3,760,000 |
I/I |
(400,000) |
2,600,980 |
|
19% |
|
| Gold Mitchell |
Executive Chairman and CEO |
• • • |
2021-09-17 |
4 |
AS |
$10.01 |
$452,964 |
D/D |
(45,262) |
109,387 |
|
-19% |
|
| Gold Mitchell |
Executive Chairman and CEO |
• • • |
2021-09-17 |
4 |
AS |
$9.40 |
$3,760,000 |
I/I |
(400,000) |
2,600,980 |
|
-19% |
|
| Fhm Life Sciences Viii, L.p. |
10% Owner |
– – • |
2021-09-17 |
4 |
D |
$0.00 |
$0 |
D/D |
(1,200,000) |
1,371,450 |
|
- |
|
| Gold Mitchell |
Executive Chairman and CEO |
• • • |
2021-09-16 |
4 |
AS |
$10.00 |
$67,696 |
D/D |
(6,768) |
154,649 |
|
-22% |
|
| Gold Mitchell |
Executive Chairman and CEO |
• • • |
2021-09-15 |
4 |
AS |
$10.00 |
$34,840 |
D/D |
(3,484) |
161,417 |
|
-15% |
|
| Gold Mitchell |
Executive Chairman and CEO |
• • • |
2021-06-28 |
4 |
AS |
$10.00 |
$34,792 |
D/D |
(3,479) |
164,901 |
|
38% |
|
| Gold Mitchell |
Executive Chairman and CEO |
• • • |
2021-06-25 |
4 |
AS |
$10.01 |
$94,865 |
D/D |
(9,473) |
168,380 |
|
36% |
|
| Gold Mitchell |
Executive Chairman and CEO |
• • • |
2021-05-20 |
4 |
AS |
$15.00 |
$18,316 |
D/D |
(1,221) |
177,853 |
|
-14% |
|
| Gold Mitchell |
Executive Chairman and CEO |
• • • |
2021-05-19 |
4 |
AS |
$15.03 |
$765,917 |
D/D |
(50,965) |
179,074 |
|
-25% |
|
200 Records found
|
|
Page 4 of 8 |
|
|
